A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2
Weiqi Wang, Shen Wang, Xianyong Meng, Yongkun Zhao, Nan Li, Tiecheng Wang, Na Feng, Feihu Yan, Xianzhu Xia
Topics & Concepts
VirologyBiologyImmunogenicityVirusImmune systemGerminal centerVirus-like particleImmunologyB cellAntibodyGeneticsGeneRecombinant DNASARS-CoV-2 and COVID-19 ResearchViral Infections and Outbreaks ResearchCRISPR and Genetic Engineering